Siemens and Pfizer Collaborate on Companion Diagnostics
Siemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer
Siemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer to design, develop and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. That pipeline includes 31projects in Phase I, 24 in Phase II, and 20 in Phase III as of November 2013. Under the agreement, Siemens will be one of Pfizer’s collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies. Siemens Clinical Laboratory (SCL), its "high-complexity" testing laboratory focused on advancing personalized medicine, will develop these companion diagnostic tests. “Companion diagnostics are an important enabler of targeted therapies for patients,” said John Hubbard, Senior Vice President and Worldwide Head of Development Operations at Pfizer.
Siemens’ is known for providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development. The agreement is to leverage these capabilities.
You can read the full release here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
